Role of bevacizumab in uterine leiomyosarcoma.

  title={Role of bevacizumab in uterine leiomyosarcoma.},
  author={Giorgio Bogani and Antonino Ditto and Fabio Martinelli and Mauro Signorelli and Valentina Chiappa and Caterina Fonatella and Roberta Sanfilippo and Umberto Leone Roberti Maggiore and Simone Ferrero and Domenica Lorusso and Francesco Raspagliesi},
  journal={Critical reviews in oncology/hematology},

Current state of the art and emerging pharmacotherapy for uterine leiomyosarcomas

The aim of this review is to describe the current pharmacotherapy for ULMS, including the ongoing clinical trials, and to suggest new alternative and innovative medical compounds that are being evaluated.

The systemic treatment of uterine leiomyosarcomas

Despite the efforts of the clinicians dealing with uterine leiomyosarcomas, the optimal therapeutic algorithm is yet to be described, and there are still a lot of unanswered questions regarding the ideal therapeutic approach.

Epigenetic Features in Uterine Leiomyosarcoma and Endometrial Stromal Sarcomas: An Overview of the Literature

The literature on uterine LMS and ESS is cross-referenced and the most relevant epigenetic studies, published between 2009 and 2022 are compiled to highlight the importance of ongoing and future studies.



Bevacizumab therapy in patients with recurrent uterine neoplasms.

Bvacizumab was well-tolerated and displayed promising anti-neoplastic activity in patients with endometrial cancer and uterine leiomyosarcoma.

Bevacizumab in Ovarian Cancer: State of the Art and Unanswered Questions

This study focuses on the results of pivotal trials, emerging data, ongoing research, and still unanswered questions about the most adequate dosage of bevacizumab and its potential activity after disease progression or rechallenge in previously treated patients.

Curative effect of bevacizumab combined with chemotherapy in advanced or recurrent uterine sarcoma.

BEV combined with chemotherapy was able to effectively control advanced or recurrent uterine sarcoma, was well-tolerated, and is considered to be a safe and effective candidate treatment for this type of tumor.

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

  • M. HensleyR. Maki D. Spriggs
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
Gemcitabine plus docetaxel is tolerable and highly active in treated and untreated patients with LMS, and Hematologic toxicity was common, but neutropenic fever and bleeding events were rare.

Bevacizumab for the treatment of cervical cancer

The use of bevacizumab in combination with other chemotherapies in cervical cancer has been proven safe and effective, with a significant improvement in overall survival of patients with advanced cervical cancer.

The potential of sunitinib as a therapy in ovarian cancer

Although clinical Phase II trials on the use of sunitinib in the treatment of OC demonstrated an acceptable profile of AEs, a greater comprehension of the toxicity of this compound is recommended.

Sorafenib for ovarian cancer

The available results from the studies which investigated the use of sorafenib for OC treatment demonstrated poor clinical benefit, and research should focus on the development of reliable predictive biomarkers to assess response and direct therapy in order to allow patient selection and improving treatment schedules maximizing the clinical benefit and simultaneously minimizing the toxicity related to the chemotherapy.

Monoclonal antibodies therapies for ovarian cancer

A brief explanation of the mechanisms of action of mAbs is offered to help readers in understanding the current role of m Abs in the treatment of OC and to identify and validate robust biomarkers for a more focused patient selection and for tailoring therapies, optimizing dose and assessing response.